Jason Yongsheng Chan: Cancer Discovery Hub’s collaboration with Illumina focusing on Asian lymphomas occuring in younger patients

Jason Yongsheng Chan, Platform Lead at Singapore Translational Cancer Consortium, shared a post by Mynn Tan, Senior Manager, Oncology Market Development at Illumina, on LinkedIn, adding:

“The Cancer Discovery Hub is excited to enter a new collaboration with Illumina on rare cancers, focusing on Asian lymphomas occuring in younger patients. This study will leverage Illumina’s WGTS platforms and will greatly enhance Singapore’s efforts in developing comprehensive genomic diagnostic assays for patients with lymphoma.

At the Cancer Discovery Hub, we strongly believe in close industry collaborations in order to bring the latest technologies to the forefront of patient care. Routine genomic diagnostics for patient care remains in the nascent stages and we hope to contribute another step forward in this endeavor with our partners!

Thanks to Mynn Tan for driving this collaboration.”

Quoting Mynn Tan’s post:

“Really excited to be working with Jason Yongsheng Chan and team to drive the development of WGTS-based genomic diagnostic technology to benefit young Asian lymphoma patients!”

Read further.
Source: Jason Yongsheng Chan/LinkedIn and Mynn Tan/LinkedIn

.